Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001999371-26-007108
Filing Date
2026-03-30
Accepted
2026-03-30 08:00:38
Documents
20
Period of Report
2026-05-07

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT tnxp-def14a_050726.htm   iXBRL DEF 14A 788928
6 GRAPHIC tonix004.jpg GRAPHIC 29453
7 GRAPHIC tonix-barchart.jpg GRAPHIC 21788
8 GRAPHIC proxy-card_1.jpg GRAPHIC 317522
9 GRAPHIC proxy-card_2.jpg GRAPHIC 326089
10 GRAPHIC tnxp_002.jpg GRAPHIC 25178
  Complete submission text file 0001999371-26-007108.txt   3262792

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE tnxp-20251231.xsd EX-101.SCH 3425
3 XBRL DEFINITION FILE tnxp-20251231_def.xml EX-101.DEF 5349
4 XBRL LABEL FILE tnxp-20251231_lab.xml EX-101.LAB 59143
5 XBRL PRESENTATION FILE tnxp-20251231_pre.xml EX-101.PRE 42613
23 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-def14a_050726_htm.xml XML 145836
Mailing Address 200 CONNELL DRIVE, SUITE 3100 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE, SUITE 3100 BERKELEY HEIGHTS NJ 07922 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36019 | Film No.: 26810025
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)